Nektar Therapeutics Inc. NKTR
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders and chronic inflammatory diseases in the United States and internationally. Its lead product candidate, rezpegaldesleukin (also…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees63
TickerNKTR
Statistics
Market Cap$1.79B
Revenue (TTM)$55.2M
Net Income-$164.1M
Net Margin-297.1%
EPS$-9.73
P/E-6.12
P/S35.96
P/B3.03
EV/EBITDA-12.05
ROE-53.6%
Dividend Yield—
Price$60.60
Data: Twelve Data · Revenue = mcap / P/S